HENRY CHANG
Vice President, Impact Initiatives

Henry Chang leads GBC effort to devise and deliver “Impact Initiatives” through global teams of member companies. These teams will coordinate a strategic mix of multiple private-sector players together with appropriate NGO, government, and local partners focused on a clear, high-impact objective. This new core GBC program was created at the behest of members, who believe that cross-functional, multiple partner collaborative programs are critical to evolving business action to a higher, results-intensive level.

Henry came to GBC with more than two decades of experience in HIV/AIDS research and advocacy. Most recently, Henry served as Chief of Global Affairs at the AIDS Healthcare Foundation (AHF), leading a global team of medical and management professionals in support of AHF’s treatment and care programs in 19 countries throughout Africa, Asia-Pacific, Eastern Europe, and Latin America. During his 11 years at AHF, Henry held various positions, including Director of Clinical Research from 1996 to 1998 and member of the AHF Board of Directors from 1998 to 2001.

Henry is a graduate of the University of California, Los Angeles, where he majored in molecular biology. From 1988 to 1992, he worked under the supervision of Dr. David Ho in the Retrovirology Laboratory at UCLA/Cedars-Sinai Medical Center as a student clinical research fellow. There he assisted in the development of a novel, quantitative assay for determining HIV viral load in blood, semen, saliva, and CSF. Henry was a founding member of the Treatment and Data Committee of the Los Angeles Chapter of the AIDS Coalition to Unleash Power (ACT-UP).

From 1995 to 1998, Henry served as a community member of numerous clinical trial protocol teams of the Adults AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases, U.S. National Institute of Health. From 1991 to 1998, he also served as community advisor to various pharmaceutical and biotechnology companies in the development of HIV therapeutic agents and diagnostic tools. In 1998, Henry joined DuPont Pharmaceuticals Company, serving as U.S. Director of Scientific and Community Relations and was subsequently promoted to Senior Director of Business Development and Strategic Planning, Global Virology Franchise.

In 2003, Henry served as a technical consultant for the World Health Organization in the development of technical and operational procedures for an emergency scale-up of antiretroviral treatment resource-limited settings—known as the “3x5” initiative. He is a member of various professional organizations, including the International AIDS Society, the American Society for Microbiology, the Infectious Disease Society of America, and the American Association for the Advancement of Science. Henry is fluent in English, Mandarin, Taiwanese and speaks basic Dutch, Spanish and Russian.